Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-human thymocyte globulin rabbit
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-human thymocyte globulin (rabbit) is a purified polyclonal IgG immunosuppressive antibody preparation derived from rabbits immunized with human thymocytes. It contains cytotoxic antibodies directed against multiple antigens on human T-lymphocytes and other immune cells. The drug acts primarily by binding to T-cell surface antigens and inducing T-cell depletion through complement-mediated cytotoxicity and apoptosis. This profound reduction in circulating T lymphocytes suppresses the host immune response, making it effective for the prevention and treatment of acute rejection in kidney transplantation. It is also used off-label for other transplant types and some hematologic conditions such as aplastic anemia[2][3][6][7]. The main FDA-approved indication is prophylaxis and treatment of acute renal allograft rejection in combination with other immunosuppressants[1][4][5].
- Brand names
- ThymoglobulinGrafalon
- Other names
- antithymocyte globulin rabbitanti-thymocyte globulin rabbitanti-human thymocyte immunoglobulin rabbit
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)CD4 (T lymphocyte surface antigen)LFA-1 (Integrin αLβ2)CD3 (T-cell surface glycoprotein CD3)CD86 (T-lymphocyte activation antigen CD86)ITGAL (Integrin alpha L (CD11a))ITGAV (Integrin αV)ITGB1 (Integrin beta-1)ITGB3 (Integrin beta-3)MR1 (Thioesterase PNKD)MHC I (MHC class I})CD1A (T-cell surface glycoprotein CD1a)
Beyond the preview
Go deeper on anti-human thymocyte globulin rabbit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-human thymocyte globulin rabbit.